PEDIATRICS Vol. 41 No. 1 January 1968, pp. 52-56
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krakoff, I. H.
Right arrow Articles by Murphy, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krakoff, I. H.
Right arrow Articles by Murphy, M. L.

HYPERURICEMIA IN NEOPLASTIC DISEASE IN CHILDREN: PREVENTION WITH ALLOPURINOL, A XANTHINE OXIDASE INHIBITOR

Irwin H. Krakoff M.D.1 and M. Lois Murphy M.D.1

1 Division of Chemotherapy Research, Sloan-Kettering Institute for Cancer Research and the Departments of Medicine and Pediatrics, Memorial and James Ewing Hospitals and Cornell University Medical College, New York

Allopurinol [4-hydroxypyrazolo (3,4-d)-pyrimidine] was used in the treatment or prevention of hyperuricemia in 21 children with various neoplastic diseases in whom there was severe hyperuricemia or in whom it might have been expected as a result of the anti-neoplastic therapy to be employed. Allopurinol was effective in reducing hyperuricemia and in preventing the hazard of uric acid nephropathy in each patient. Previous experience with such patients had been characterized by the frequent occurrence of hyperuricemia and uric acid nephropathy. Allopurinol has produced no toxicity, except for the occasional occurrence of a mild skin rash. It is considered a useful agent in the treatment or prevention of uric acid nephropathy in children with leukemia and lymphoma.

Submitted on June 5, 1967
Accepted on August 22, 1967




This article has been cited by other articles:


Home page
 Journal of Pharmacy PracticeHome page
B. Bickert and A. Reilly
Pediatric Tumor Lysis Syndrome
Journal of Pharmacy Practice, December 1, 2004; 17(6): 447 - 454.
[Abstract] [PDF]

Home page
 JCOHome page
C.-H. Pui, H. H. Mahmoud, J. M. Wiley, G. M. Woods, G. Leverger, B. Camitta, C. Hastings, S. M. Blaney, M. V. Relling, and G. H. Reaman
Recombinant Urate Oxidase for the Prophylaxis or Treatment of Hyperuricemia in Patients With Leukemia or Lymphoma
J. Clin. Oncol., February 1, 2001; 19(3): 697 - 704.
[Abstract] [Full Text] [PDF]